At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
RYZB RayzeBio, Inc.
Halted 02-23 16:00:00 EST
62.49
+0.00
0.00%
High62.49
Low62.49
Vol0.00
Open62.49
D1 Closing62.49
Amplitude0.00%
Mkt Cap3.74B
Tradable Cap2.18B
Total Shares59.92M
T/O17.33M
T/O Rate0.00%
Tradable Shares34.82M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Introduction
Company Name.
RayzeBio, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company's lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs). It also develops RYZ801, a novel proprietary peptide that targets GPC3 for delivery of Ac225 for the treatment of hepatocellular carcinoma (HCC); RYZ811, a paired diagnostic imaging agent with the peptide binder, chelator, and Ga68 as the radioisotope; and a novel proprietary small molecule that targets CA9 for delivery of Ac225 for the treatment of ccRCC. The company was incorporated in 2020 and is based in San Diego, California.